ENDRA Life Sciences is engaged in developing technology in clinical diagnostic ultrasound for patient access to the diagnosis and treatment of various medical conditions. Co.'s Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology uses a pulsed energy source, radio-frequency, to generate ultrasonic waves in tissue. These waves are then detected with ultrasound equipment and used to create images and other forms of data using its proprietary algorithms. Co. is also developing TAEUS for incorporation into new ultrasound systems manufactured by companies such as General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center. The NDRA average annual return since 2017 is shown above.
The Average Annual Return on the NDRA average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NDRA average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NDRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|